Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens

Virus Research

Volumn 195, Issue , 2015, Pages 35-42

  Xue, Chunyi ^a   Tian, Guobin ^b   Chen, Xianxian ^a   Liu, Qiliang ^a   Ma, Jun ^a   Xu, Shun ^a   Li, Xiaoming ^a   Chen, Hualan ^b   Cao, Yongchang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b AGRO ENVIRONMENTAL PROTECTION INSTITUTE   (China)

Author keywords

H5N1; Immune response; Nucleoprotein; Vaccine; Virus like particles

Indexed keywords

ANTIBODY; ANTIGEN; HEMAGGLUTININ; NUCLEOPROTEIN; SIALIDASE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE 3 VACCINE; VIRUS LIKE PARTICLE 4 VACCINE; VIRUS VACCINE; CORE PROTEIN; EMULSION; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; M1 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; NA PROTEIN, INFLUENZA A VIRUS; NP PROTEIN, INFLUENZA A VIRUS; RNA BINDING PROTEIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACULOVIRUS; CELLULAR IMMUNITY; CHICKEN; CONTROLLED STUDY; EMULSION; FEMALE; GENOME; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA A (H5N1); INFLUENZA VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PROTECTION; SF9 CELL LINE; VACCINATION; VIRUS LIKE AGENT; ADMINISTRATION AND DOSAGE; ANIMAL; BACULOVIRIDAE; BAGG ALBINO MOUSE; BLOOD; CROSS PROTECTION; GENE VECTOR; GENETICS; IMMUNOLOGY; INFLUENZA IN BIRDS; INFLUENZA VIRUS A H5N1; INTRAMUSCULAR DRUG ADMINISTRATION; MONONUCLEAR CELL; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES;

GALLUS GALLUS; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; CHICKENS; CROSS PROTECTION; EMULSIONS; FEMALE; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; LEUKOCYTES, MONONUCLEAR; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; RNA-BINDING PROTEINS; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 84919338041     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.09.018     Document Type: Article

References (38)

1. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., Naghdaliyev A., Peiris J.S., Shindo N., Soeroso S., Uyeki T.M. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 2008, 358(3):261-273.
2. Bessa J., Schmitz N., Hinton H.J., Schwarz K., Jegerlehner A., Bachmann M.F. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur. J. Immunol. 2008, 38(1):114-126.
3. Braciale T.J., Yap K.L. Role of viral infectivity in the induction of influenza virus-specific cytotoxic T cells. J. Exp. Med. 1978, 147(4):1236-1252.
4. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., Kumar N.M., Pushko P., Smith G., Tumpey T.M., Ross T.M. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008, 3(1):e1501.
5. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., Massare M., Pushko P., Mytle N., Rowe T., Smith G., Ross T.M. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25(19):3871-3878.
6. Cessi D., Nardelli L. Vaccination against Newcastle disease: efficacy of an oil emulsion vaccine. Avian Pathol. 1974, 3(4):247-253.
7. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 2004, 59(1):1-15.
8. Demicheli V., Rivetti D., Deeks J.J., Jefferson T.O. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 2004, 3:CD001269.
9. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., Nabel G.J. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23(46-47):5404-5410.
10. Fu T.M., Grimm K.M., Citron M.P., Freed D.C., Fan J., Keller P.M., Shiver J.W., Liang X., Joyce J.G. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27(9):1440-1447.
11. Gillim-Ross L., Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin. Microbiol. Rev. 2006, 19(4):614-636.
12. Gschoesser C., Almanzar G., Hainz U., Ortin J., Schonitzer D., Schild H., Saurwein-Teissl M., Grubeck-Loebenstein B. CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein. Vaccine 2002, 20(31-32):3731-3738.
13. Haynes J.R. Influenza virus-like particle vaccines. Expert Rev. Vaccines 2009, 8(4):435-445.
14. Horimoto T., Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin. Microbiol. Rev. 2001, 14(1):129-149.
15. Huber V.C., Lynch J.M., Bucher D.J., Le J., Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 2001, 166(12):7381-7388.
16. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., Makarova N., Perez D.R., Macdonald G.H., McCullers J.A. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. 2006, 13(9):981-990.
17. Jayasekera J.P., Moseman E.A., Carroll M.C. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J. Virol. 2007, 81(7):3487-3494.
18. Kang S.M., Guo L., Yao Q., Skountzou I., Compans R.W. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J. Virol. 2004, 78(18):9624-9632.
19. Kang S.M., Song J.M., Quan F.S., Compans R.W. Influenza vaccines based on virus-like particles. Virus Res. 2009, 143(2):140-146.
20. Kang S.M., Yoo D.G., Lipatov A.S., Song J.M., Davis C.T., Quan F.S., Chen L.M., Donis R.O., Compans R.W. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE 2009, 4(3):e4667.
21. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., Heaton P.M., Tumpey T.M., Ross T.M. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26(42):5393-5399.
22. Matassov D., Cupo A., Galarza J.M. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol. 2007, 20(3):441-452.
23. McMichael A.J., Michie C.A., Gotch F.M., Smith G.L., Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J. Gen. Virol. 1986, 67(Pt 4):719-726.
24. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003, 11(9):438-444.
25. Prel A., Le Gall-Recule G., Jestin V. Achievement of avian influenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian influenza strains in ducks. Avian Pathol. 2008, 37(5):513-520.
26. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23(50):5751-5759.
27. Qiao C., Tian G., Jiang Y., Li Y., Shi J., Yu K., Chen H. Vaccines developed for H5 highly pathogenic avian influenza in China. Ann. N. Y. Acad. Sci. 2006, 1081:182-192.
28. Quan F.S., Huang C., Compans R.W., Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 2007, 81(7):3514-3524.
29. Quan F.S., Steinhauer D., Huang C., Ross T.M., Compans R.W., Kang S.M. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008, 26(26):3352-3361.
30. Ross T.M., Xu Y., Bright R.A., Robinson H.L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 2000, 1(2):127-131.
31. Rudolf M.P., Fausch S.C., Da Silva D.M., Kast W.M. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 2001, 166(10):5917-5924.
32. Suguitan A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., Luke C.J., Murphy B., Swayne D.E., Kemble G., Subbarao K. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006, 3(9):e360.
33. Tian G., Zeng X., Li Y., Shi J., Chen H. Protective efficacy of the H5 inactivated vaccine against different highly pathogenic H5N1 avian influenza viruses isolated in China and Vietnam. Avian Dis. 2010, 54(Suppl. 1):287-289.
34. Townsend A.R., Skehel J.J. The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J. Exp. Med. 1984, 160(2):552-563.
35. Webby R.J., Webster R.G. Are we ready for pandemic influenza?. Science 2003, 302(5650):1519-1522.
36. Wen Z., Ye L., Gao Y., Pan L., Dong K., Bu Z., Compans R.W., Yang C. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res. 2009, 84(3):215-224.
37. Yap K.L., Ada G.L., McKenzie I.F. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978, 273(5659):238-239.
38. Zhirnov O.P., Isaeva E.I., Konakova T.E., Thoidis G., Piskareva L.M., Akopova I.I., Kartashov A., Altstein A.D., Ilyinskii P.O., Shneider A.M. Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP M1 and NS1. Influenza Other Respir. Viruses 2007, 1(2):71-79.